421 related articles for article (PubMed ID: 28156002)
1. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
2. Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Van Hemelryk A; Tomljanovic I; de Ridder CMA; Stuurman DC; Teubel WJ; Erkens-Schulze S; Verhoef EI; Remmers S; Mahes AJ; van Leenders GJLH; van Royen ME; van de Werken HJG; Grudniewska M; Jenster GW; van Weerden WM
Cells; 2022 Nov; 11(22):. PubMed ID: 36429059
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP
Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486
[TBL] [Abstract][Full Text] [Related]
4. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
[TBL] [Abstract][Full Text] [Related]
6. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
7. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.
Lam HM; Nguyen HM; Labrecque MP; Brown LG; Coleman IM; Gulati R; Lakely B; Sondheim D; Chatterjee P; Marck BT; Matsumoto AM; Mostaghel EA; Schweizer MT; Nelson PS; Corey E
Eur Urol; 2020 Feb; 77(2):144-155. PubMed ID: 31227306
[TBL] [Abstract][Full Text] [Related]
8. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
9. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.
Lam HM; McMullin R; Nguyen HM; Coleman I; Gormley M; Gulati R; Brown LG; Holt SK; Li W; Ricci DS; Verstraeten K; Thomas S; Mostaghel EA; Nelson PS; Vessella RL; Corey E
Clin Cancer Res; 2017 May; 23(9):2301-2312. PubMed ID: 27993966
[No Abstract] [Full Text] [Related]
10. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation.
Wu P; Xu R; Chen X; Zhao Y; Tan D; Zhao Y; Qin W; Zhang C; Ge X; Shi C
Aging (Albany NY); 2020 Feb; 12(4):3848-3861. PubMed ID: 32092044
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE; Day A; Bergom HE; Larson G; Ali A; Ludwig M; Boytim E; Coleman I; Corey E; Plymate SR; Nelson PS; Hwang JH; Drake JM
Mol Cancer Res; 2024 May; 22(5):452-464. PubMed ID: 38345532
[TBL] [Abstract][Full Text] [Related]
14. An original patient-derived xenograft of prostate cancer with cyst formation.
Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
[TBL] [Abstract][Full Text] [Related]
15. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.
Valta MP; Zhao H; Saar M; Tuomela J; Nolley R; Linxweiler J; Sandholm J; Lehtimäki J; Härkönen P; Coleman I; Nelson PS; Corey E; Peehl DM
Clin Exp Metastasis; 2016 Apr; 33(4):325-37. PubMed ID: 26873136
[TBL] [Abstract][Full Text] [Related]
16. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
17. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
18. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U; Hofmann MH; Friedbichler K; Baumgartinger R; Adam PJ; Solca F; Kraut N; Nguyen HM; Corey E; Liu G; Sprenger CC; Plymate SR; Bogenrieder T
Mol Cancer Ther; 2020 Apr; 19(4):1059-1069. PubMed ID: 32054790
[TBL] [Abstract][Full Text] [Related]
20. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
